Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05333107 · ClinicalTrials.gov registry record · Phase 1
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II
A Phase 1 study of Healthy Volunteers; High Cholesterol, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 2
- Study locations
NCT05333107: Completed Phase 1 study of Healthy Volunteers; High Cholesterol, sponsored by Novo Nordisk A/S.
NCT05333107 is a Phase 1 study of Healthy Volunteers; High Cholesterol that has completed, run by Novo Nordisk A/S. The registered enrollment target is 152 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (153% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05333107, a Phase 1 study of Healthy Volunteers; High Cholesterol, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol). Participants will only receive 2 of the 3 tablet formulations. The treatments participants get are decided by chance. Participants will receive 1 formulation for 10 days (first treatment period) and the other formulation for 5 days (second treatment period). The study will last up to 96 days. Only men can participate in this clinical study.
Primary Outcome
Measured in h \* nmol/L
Conditions Studied
Interventions
- DRUG NNC0385-0434 G
- DRUG NNC0385-0434 F
- DRUG NNC0385-0434 B
Study Locations (2)
California
- Altasciences - Cypress
- Altasciences Clinical Los Angeles, Inc. - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2022-04-12 |
| Est. Completion | 2022-09-23 |
| Phase | Phase 1 |
What the finished NCT05333107 record still lists
NCT05333107 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (153% higher).
The record links to 1 condition, with Healthy Volunteers; High Cholesterol appearing as the primary indexed condition, and to 3 interventions - of which NNC0385-0434 G is the first listed.
NCT05333107 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05333107 about?
NCT05333107 is a clinical study titled "A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II". In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol). Participants will only receive 2 of the 3 tablet formulations. The treatments participants get are decided...
What is the current status of trial NCT05333107?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2022-04-12. Estimated completion is 2022-09-23.
What conditions does trial NCT05333107 study?
This clinical trial studies the following conditions: Healthy Volunteers; High Cholesterol.
What interventions are being tested in trial NCT05333107?
The interventions under investigation include: NNC0385-0434 G (DRUG), NNC0385-0434 F (DRUG), NNC0385-0434 B (DRUG).
Who is sponsoring clinical trial NCT05333107?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05333107 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05333107's enrollment target sits among peer trials
152 359th of 2000 higher than 1,638 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI